Biofactories Plants

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety. For this porpoise the introduction of genes has been done of interest in heterologous organisms, which thus become ” bio-factories ” production. In the production of therapeutic products there are two important expression systems :

      1. prokaryotic systems have great advantages from the economic point of view due to their high production levels but such systems are not capable of post-translational modifications generate, limiting its use to that of smaller, less complex proteins
      2. mammalian systems cell lines, which have a high cost in terms of production, are able to generate therapeutic protein complex with posttranslational modifications . Currently have intensified efforts to develop new production systems to obtain safe recombinant molecules at low cost. In this sense , the plants begin to become a reality as a body that behave like living factories that produce low-cost drugs and even human proteins of therapeutic interest and health. They seem clear advantages with respect to other production techniques can be derived from this “bio-factories ” . The use of plants as bioreactors for the production of recombinant proteins, it is a possible alternative. That is why the advantages associated with the production of recombinant proteins in plant bioreactors they have transformed into a highly competitive option. The main advantage of plants as production systems is almost unlimited availability of biomass that can be obtained using existing infrastructure for planting, harvesting, storage and processing of crops.

In terms of security the production of therapeutic proteins in plants offers a number of advantages over the use of mammalian cell lines, since they present less risk of contamination by animal pathogens, as they are not virally infected animals and the possible turn plant viruses that may exist are not transmissible to humans.


More on Agroaxis

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety.
The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry.

AGROAXIS decided to use and adapt the System NGS® to all their technology platforms to respond to the growing need of a new culture technologies and as a result of water scarcity and soil low yields increasingly overexploited.

Latest News

  • Agroaxis hires three more technologists with the grant Inncorpora TU of the Ministry of Economy and Competitiveness
  • Agroaxis creates the first GreenMab┬« technology platform with plants Snuff “Human “Insulin for obtaining
  •  

    Copyright 2013 Agroaxis. All Rights Reserved